Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
That's going to surprise a number of people, including me
The updated regulatory timeline: May 21, 2026: TRIUMPH-1 top-line data released June 2026: Detailed data presented at the 86th ADA Scientific Sessions Q4 2026: NDA submission to FDA (obesity indication) 2027: FDA review period (6-10 months standard
Conclusion In conclusion, the emerging observation that some complications of diabetes are associated with an hyperactivation of RAAS has provided the pathophysiological basis to study the effects of GLP1-RA and SGLT2-i on RAAS to better explain the cardio-reno-protective effect demonstrated by the clinical trials, beyond their role on glucose control
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al
)
